Making Waves in Pain and Opioid Research at BWH
McGraw Family Opioid Innovator Award
October 22nd marked the first annual McGraw Family Opioid Innovator Award and Shark Tank. This year the Brigham Research Institute collaborated with Dr. Scott Weiner/ the POPI program and the McGraw family to award two $50,000 gifts to two opioid and pain research innovators of BWH. CONGRATULATIONS to the two winners, Dr. Joji Suzuki and Dr. Athena Petrides and congratulations to all the finalists for a job well done! Please see below for information on winners, finalists and their projects!
McGraw Family Opioid Award Fall 2019 Winners

Athena Petrides, PhD, Assistant Professor, Pathology, BWH
Project: DigiToxRx: Treating Pain is No Longer Painful
Joji Suzuki, MD, Assistant Professor, Psychiatry, BWH
Project: Pilot study of cannabidiol (CBD) for the treatment of opioid use disorder
McGraw Family Opioid Award Fall 2019 Finalists
Peter Chai, MD, MMS, Assistant Professor, Emergency Medicine, BWH
Project: Enabling smart sewers to measure community level opioid and naloxone consumption

Christopher Connor, MD, PhD Assistant Professor, Anesthesiology, BWH
Project: Imaging opioid effects, tolerance and addiction in C. elegans

Jason R. Yong, MD, MBA, Instructor, Pain Medicine, BWH
Smart Pill Dispenser to Enhance Opioid Compliance and Patient Outcomes

To read ALL project summaries click here .

For more information on how to apply for the McGraw Family Opioid Award Fall 2020,
Contact: Gloria Brand, POPI Senior Program Manager at gbrand@bwh.harvard.edu
Funding Opportunities
The purpose of this Funding Opportunity Announcement (FOA) is to encourage developmental and exploratory research focused on determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also seek to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these populations.
Agency: National Institute of Health
FOA: PAR-18-745
Amount: $200,000
Due Date: November 14, 2019
The purpose of this FOA is to support one Multisite Clinical Center (MCC) to implement the enrollment and multimodal longitudinal assessment of a large cohort of EITHER an acute musculoskeletal trauma OR an acute peri-operative pain event patients to identify biosignatures for resilience to and/or the transition from acute to chronic pain.
Agency: National Institute of Neurological Disorders and Stroke (NINDS)
NO: NOT-AT-11-002
Amount: $3,400,000
Due Date: November 26, 2019
Supports translational research that will accelerate the movement of evidence-based ideas in chronic pain management research into clinical applications, including healthcare products, technologies, and/or clinical practice guidelines. TRA applications should explain how the proposed work will inform the development, refinement, and/or revision of existing standards of care, recommendations, or guidelines for managing chronic pain. 
Agency: Department of Defense
CFDA: 12.420 - Military Research and Development
Amount: $4,480,000
Due Date: December 6, 2019
Aims to speed scientific solutions to stem the national  opioid  public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement.
Agency: US Department of Health and Human Services (HHS)
CFDA: 93.213
Amount: TBD
Due Date: January 8, 2020
Invites innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories.
FOA: PAS-18-625
Amount: Varies
Due Date: November 16, 2019
Promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. The focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints.
FOA: RFA-NS-18-041
Amount: Varies
Due Date: November 25, 2019

The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. 
FOA: PAR-20-035
Amount:   $300,000
Due Date: March 17, 2020
To establish a Data Center to coordinate and analyze single cell and other molecular data sets generated by Single Cell Opioid Responses in the Context of HIV (SCORCH) and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community.  
FOA: RFA-DA-20-027
Amount: Varies
Due Date: January 15, 2020
Invites applications for infrastructure support to advance the development of efficacy and/or effectiveness research on recovery support services for those who were or who are being maintained on medications for the treatment of opioid use disorder. 
FOA: RFA-DA-20-014
Amount:  $400,000
Due Date: November 19, 2019
The purpose of the Rat Opioid Genome Project (ROGP) is two-fold. The first goal is to identify genetic, genomic, and molecular (epi)genetic variants that underlie phenotypes associated with vulnerability to distinct stages along the opioid use disorder (OUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery). The second is to identify genetic, genomic, and molecular (epi)genetic variants underlying phenotypes of conditions associated with OUD (e.g. respiratory depression, hyperalgesia, constipation, urinary retention, etc.). 
FOA: RFA-DA-20-010
Amount: Varies
Due Date: November 19, 2019
The mission of EPPIC-Net is to improve the treatment of acute and chronic pain and reduce reliance on opioids. This will be accomplished by accelerating the early phase testing of non-addictive pharmacologic and device strategies for alleviating pain submitted by industry and academic investigators.
ROA: OTA-19-008
Amount: Varies
Due Date: December 20, 2019
The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.
NOT-OD-20-008
Amount: Varies
Due Date: July 7, 2020
Featured Innovator Publications
Scott Weiner, MD, MPH - Emergency Medicine
Brian T. Bateman, MD - Anesthesiology Perioperative and Pain Medicine
Addressing Racial and Ethnic Disparities in Pain Management in the Midst of the Opioid Crisis- November 2019


Ethan Brovman, MD; Richard Urman, MD, - Anesthesiology Perioperative and Pain Medicine
Ethan Brovman, MD; Richard Urman, MD; Sascha Beutler, MD, PhD- Anesthesiology Perioperative and Pain Medicine
The Association Between Potential Opioid-Related Adverse Drug Events and Outcomes in Total Knee Arthroplasty: A Retrospective Study- October 2019


Jeffrey Katz, MD; Seoyoung Kim, MD, ScD; Daniel H. Solomon, MD - Rheumatology, Inflammation, and Immunity
Yinzhu Jin; Joyce Lii - Pharmacoepidemiology & Pharmacoeconomics
Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees- October 2019

Upcoming Events
Half and Half MAT Waiver Training
November 22, 2019
International Conference on Opioids 2020
May 30, 2020

´╗┐MARK YOUR CALENDARS!!!

The next POPI Meeting will be held
Wednesday, December 11, 2019
3:00 PM - 4:30 PM
Hale 05010

If you would like to attend please RSVP to the right.

For any additional questions or concerns contact Gloria Brand, Senior Program Manager
Pain and Opioid Innovation Program
617-278-0516

POPI Meeting
LOCATION
Hale BTM room 05010 or Zoom

DATE AND TIME
12/11/19 3:00pm - 12/11/19 4:30pm

Updates on POPI program website and program structure. Meeting will be interactive.
I'll be there!
Maybe
I can't make it